<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805908</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2011-PETRA</org_study_id>
    <nct_id>NCT01805908</nct_id>
  </id_info>
  <brief_title>Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)</brief_title>
  <acronym>PETRA</acronym>
  <official_title>Imaging With 111In-Pertuzumab to Predict Response to Trastuzumab in HER2 Positive Metastatic or Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective of the study is to improve the care of women with Human Epidermal&#xD;
      Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by&#xD;
      using a radio-labelled biomarker with whole body Single Photon Emission Computed Tomography&#xD;
      (SPECT) imaging to predict who will respond to treatment with Trastuzumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual is very poor&#xD;
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tumour SUV (Standardized Uptake Value) from baseline to Day 8.</measure>
    <time_frame>8 days</time_frame>
    <description>The imaging outcome for exploring the association between imaging and clinical outcome is the percent change in tumour SUV from baseline to Day 8 (Day 8 SUV - baseline SUV) /baseline SUV times 100%. The Positron Emission Tomography Evaluation Response Criteria In Solid Tumours (PERCIST) criterion will be used to measure SUV change.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety attributable to 111In-Pertuzumab injections</measure>
    <time_frame>3 months</time_frame>
    <description>The safety, i.e. toxicities, attributable to 111In-Pertuzumab injections will be evaluated using the National Cancer Institute (NCI) Common Termination for Adverse Events Version 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) and tumour and normal tissue localization properties of 111In-PmAb will be measured.</measure>
    <time_frame>3 months</time_frame>
    <description>The pharmacokinetics of 111In-PmAb and tumour and normal tissue localization properties of 111In-PmAb will be measured. Standard PK parameters (t1/2 alpha, t1/2β, V1, Vss and CL) will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal mass dose of 111In-PmAb</measure>
    <time_frame>3 months</time_frame>
    <description>The dose of 111In-PmAb that is associated with the optimal SPECT-CT images will be established.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumour SUV from Baseline to Day 36</measure>
    <time_frame>3 months</time_frame>
    <description>The imaging outcome for exploring the association between imaging and clinical outcome is the percent change in tumour SUV from baseline to Day 36 (Day 36 SUV - baseline SUV) /baseline SUV times 100%. The Positron Emission Tomography Evaluation Response Criteria In Solid Tumours (PERCIST) criterion will be used to measure SUV change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response (complete or partial) to treatment will be measured using Response Evaluation Criteria In Solid Tumours (RECIST) criteria.</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical response (complete or partial) to treatment will be measured using Response Evaluation Criteria In Solid Tumours (RECIST) criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>111In-Pertuzumab + SPECT-CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>111In-Pertuzumab + SPECT-CT</intervention_name>
    <description>111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.</description>
    <arm_group_label>111In-Pertuzumab + SPECT-CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Metastatic, locally recurrent (local recurrence not amenable to surgical resection of&#xD;
             curative intent), or locally advanced (T3 or T4, any N, M0) adenocarcinoma of the&#xD;
             breast.&#xD;
&#xD;
          2. Tumour HER2 positive by immunohistochemistry for HER2 protein over-expression or by&#xD;
             Fluorescence in situ Hybridization (FISH) for HER2 gene amplification, as defined by&#xD;
             American Society of Clinical Oncology/College of American Pathologists guidelines&#xD;
&#xD;
          3. Initiating treatment with TmAb&#xD;
&#xD;
          4. Clinically measurable disease (by RECIST for patients with metastatic disease).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male gender.&#xD;
&#xD;
          2. Less than 18 years of age.&#xD;
&#xD;
          3. Life expectancy &lt; 12 weeks.&#xD;
&#xD;
          4. Only site of metastases is liver.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of &gt; 2.&#xD;
&#xD;
          6. Currently receiving PmAb or lapatinib for treatment of MBC.&#xD;
&#xD;
          7. Having received TmAb as adjuvant therapy within the previous 6 months.&#xD;
&#xD;
          8. Required to receive another radiopharmaceutical during the first week of the study.&#xD;
&#xD;
          9. Hypersensitivity to monoclonal antibodies.&#xD;
&#xD;
         10. Left Ventricular Ejection Fraction (LVEF) &lt; 50% at baseline (within 42 days of study&#xD;
             registration) as determined by either echocardiogram (ECHO) or Multi-Gated Acquisition&#xD;
             (MUGA) scan.&#xD;
&#xD;
         11. Hematology and/or biochemistry parameters outside acceptable ranges:&#xD;
&#xD;
               -  absolute neutrophil count &lt;1,500 cells/mm3,&#xD;
&#xD;
               -  platelet count &lt;100,000 cells/mm3,&#xD;
&#xD;
               -  hemoglobin &lt;9 g/dL,&#xD;
&#xD;
               -  total bilirubin &gt; upper limit of normal (ULN) (unless subject has documented&#xD;
                  Gilbert's Syndrome),&#xD;
&#xD;
               -  aspartate aminotransferase (AST) [serum glutamic oxaloacetic transaminase(SGOT)]&#xD;
                  and alanine aminotransferase (ALT) [serum glutamic pyruvate transaminase(SGPT)]&#xD;
                  &gt;2.5 × ULN,&#xD;
&#xD;
               -  serum creatinine &gt;2.0 mg/dL or 177 μmol/L,&#xD;
&#xD;
               -  alanine aminotransferase (ALP) &gt;2.5 x ULN.&#xD;
&#xD;
         12. Known pregnancy or lactating female (e.g. positive serum beta-human chorionic&#xD;
             gonadotropin (B-hCG) pregnancy test).&#xD;
&#xD;
         13. For women of childbearing potential, failure to agree to use a highly effective form&#xD;
             of contraception (patient and/or partner, e.g., surgical sterilization) or two&#xD;
             effective forms of contraception (a reliable barrier method in conjunction with&#xD;
             spermicidal jelly, birth control pills, or contraceptive hormone implants) and to&#xD;
             continue its use for the duration of study treatment.&#xD;
&#xD;
         14. Any condition, which in the investigator's opinion would not make the patient a&#xD;
             suitable candidate for inclusion in the trial.&#xD;
&#xD;
         15. Participation in another clinical trial.&#xD;
&#xD;
         16. Inability to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Levine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group, McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raymond Reilly</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Pritchard</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>June 3, 2016</last_update_submitted>
  <last_update_submitted_qc>June 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>breast cancer</keyword>
  <keyword>herceptin</keyword>
  <keyword>imaging</keyword>
  <keyword>tumour response</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>SPECT-CT</keyword>
  <keyword>pertuzumab</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>locally advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

